Project Grant R43TR004975

Award Date 12/15/23
Completion Date 12/14/24
Dollars Obligated $1.2M
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $255,991 National Science Foundation project grant supports the development of an automated system for rapid analysis of biopsy samples by Amcyt, Inc. The system aims to increase the efficiency and accessibility of fine needle aspiration biopsy procedures through three automated processes: sample smearing, staining, and image capture. This addresses a critical need to improve biopsy analytics and potentially eliminate up to 20% of failed procedures due to sampling errors. By automating...
This $305,000 Small Business Innovation Research (SBIR) Phase I project, awarded by the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a microchip-based technology that uses sound waves and electric fields to manipulate cells and sequentially deliver customizable genetic materials. The goal is to make advanced cell engineering more accessible and enable a wider range of users to perform complex cellular modifications...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
This $275,000 Project Grant awarded by the National Science Foundation (NSF) under the CFDA 47.084 Technology, Innovation, and Partnerships (TIP) program supports the development of a novel tissue-engineered platform for cancer modeling and drug screening by Vivosphere LLC, a small, woman-owned, and minority-owned business located in Auburn, Alabama. The key product being developed is a more physiologically relevant, high-throughput screening model that can improve the translation rate between...
This SBIR Phase I Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $264,016 to Surgical Vision Systems, Inc. to design and develop a novel robotic surgery system for improving microvascular anastomotic procedures. The key objectives are to: 1) develop an optical coherence tomography imaging system integrated with a robotic microvascular suturing tool, 2) test the accuracy of the imaging...
This $295,924 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to develop and demonstrate a high-yield microfluidic device for the enrichment and capture of CD3+ T cells. This device is intended to improve the manufacturing of autologous and allogenic engineered cell therapies such as CAR-T, which currently have time-consuming and costly production processes. The key objectives are to (1)...
The National Science Foundation awarded Juggernaut Life Sciences LLC a $256,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a smart, semi-autonomous fluid drainage system for surgical procedures. The one-year project will create a prototype robotic device with integrated ultrasound probe, anesthetic syringe, scalpel, and aspiration needle to demonstrate the feasibility of semi-autonomously performing paracentesis procedures to drain...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), provides $249,000 to Case Western Reserve University to develop an ultrafast photoacoustic histology platform for real-time intraoperative diagnosis. The project aims to create a structured illumination ultraviolet photoacoustic microscopy system capable of...
The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...

DEVICE AUTOMATION OF AN FDA-CLEARED CD-MICROFLUIDIC PLATFORM FOR RAPID TISSUE MICROSIZING - ABSTRACT THERE IS A NEED IN THE MARKET FOR A TRUE PLATFORM TECHNOLOGY THAT AUTOMATES THE TISSUE PROCESSING EXPERIENCE. SYNTR HEALTH TECHNOLOGIES HAS DEDICATED THE LAST SIX YEARS DEVELOPING THE TECHNOLOGY THAT CAN STREAMLINE TISSUE PROCESSING. OUR FDA-CLEARED SYNTRFUGE SYSTEM AND SYNTRFPU360, IS A PLATFORM TECHNOLOGY THAT CAN PROCESS A VARIETY OF DIFFERENT TISSUE TYPES SUCH AS CANCER TUMORS OF KIDNEY, LIVER, BRAIN, AND BREAST TISSUE BY DISSOCIATING THEM INTO SINGLE CELLS TO BETTER UNDERSTAND TUMOR TISSUE HETEROGENEITY, OF WHICH THE SINGLE CELL ANALYSIS MARKET IS VALUED AT $3.3 BILLION AND EXPECTED TO GROW TO $6.3 BILLION BY 2026. AS WELL, OUR PLATFORM CAN BE USED TO MICROSIZE AUTOLOGOUS ADIPOSE TISSUE TO BE USED FOR REINJECTION BACK INTO THE PATIENT TO TREAT MEDICAL CONDITIONS OF THE AGING POPULATION SUCH AS DIABETIC FOOT ULCERS AND KNEE OSTEOARTHRITIS. SYNTR HAS SUCCESSFULLY COMPLETED AN SBIR PHASE I GRANT WHERE WE UTILIZED MICRONIZED ADIPOSE TISSUE TO HEAL DIABETIC ULCERS IN AN ANIMAL MODEL. THIS STUDY HAD AN IMPORTANT ROLE IN DEVELOPING A TREATMENT MODALITY THAT TRANSLATED SUCCESSFULLY INTO HUMANS. PRELIMINARY HUMAN CLINICAL DATA IS SHOWING SIGNIFICANT DIABETIC FOOT ULCER WOUND CLOSURE WITHIN 3- 5 WEEKS USING AUTOLOGOUS ADIPOSE TISSUE PROCESSED IN OUR PLATFORM. THE DIABETIC FOOT ULCER MARKET IS CURRENTLY VALUED AT $1.98 BILLION WITH A CAGR OF 8.2%. THIS HIGH GROWTH POTENTIAL IS ATTRIBUTED TO THE INCREASE OF THE DIABETIC POPULATION. ADDITIONALLY, THE USE OF MICROSIZED ADIPOSE TISSUE IS SHOWING GREAT PROMISE IN INTRA-ARTICULAR INJECTIONS TO KNEE JOINTS FOR THE TREATMENT OF OSTEOARTHRITIS (OA). THE KNEE OA MARKET IN NORTH AMERICA IS CURRENTLY VALUED AT $5.9 BILLION AND GROWING AT T CAGR OF 8.8%. OVER 88% OF INDIVIDUALS WITH OA ARE 45 OR OLDER. THE HIGH GROWTH POTENTIAL OF THIS MARKET IS LARGELY ATTRIBUTED TO THE INCREASE OF THE AGING POPULATION ALONG WITH THE INCREASE IN OBESITY RATES. OUR PLATFORM TECHNOLOGY FOR THE RAPID PROCESSING AND/OR MICROSIZING OF TISSUES CAN DISRUPT THESE MARKETS IN A MAJOR WAY. THE AUTOMATION OF THIS TECHNOLOGY IN THIS PHASE I SBIR IS PARAMOUNT TO INCREASE FAVORABILITY IN THE ADOPTION OF THIS MUCH NEEDED TECHNOLOGY IN VARIOUS MEDICAL FIELDS.

Posted 12/8/23, 12:00 AM